Transl Clin Pharmacol.  2014 Jun;22(1):11-12.

Repeated Administration of Newly Synthesized Aceclofenac Sustained Release Form Causes Agranulocytosis: Case Report of an Unforeseen Adverse Event during the Phase 1 Trial

• Jin H
• Zheng R
• Kim B
• Yim SV

Abstract

Aceclofenac is a non-steroidal anti-inflammatory drug (NSAIDs) for inflammatory diseases. In this report, we report a serious adverse event (AE) occurred during the phase I clinical trial for a new sustained-release (SR) formulation of aceclofenac. There was a serious adverse event (AE), agranulocytosis, induced by aceclofenac SR form. An open-labeled, repeated-doses, randomized, crossover study was conducted at Kyung Hee University Hospital and 26 Korean healthy male volunteers were enrolled. All subjects received both aceclofenac SR 200 mg once daily and aceclofenac IR 100 mg twice daily for 4 days with 11 days washout period. After 11 days washout period, one subject showed a serious decrease in the segment neutrophil (267/mm3) on a laboratory test prior to the reference drug administration in period 2. We first report a case of agranulocytosis, during a phase I clinical trial.

Keyword

Aceclofenac; Non-steroidal anti-inflammatory drug (NSAIDs); Serious adverse event (AE); Agranulocytosis

MeSH Terms

Agranulocytosis*
Cross-Over Studies
Humans
Male
Neutrophils
Volunteers

Reference

References

1. Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004; 5:1347–1357. doi: 10.1517/14656566.5.6.1347.

2. Datta K, Ghosh RK, Ghosh SM. Serious neutropenia following etanercept administration in a 62 years female patient of rheumatoid arthritis. J Assoc Physicians India. 2010; 58:643–644.

3. Lobo I, Pinto A, Ferreira M, Oliveira J, Sanches M, Reis E, et al. Non-pseudomonal ecthyma gangrenosum present in diclofenac-induced agranulocytosis. Eur J Dermatol. 2008; 18:350–351. doi: 10.1684/ejd.2008.0410.

4. Ho ML, Chang JK, Chuang LY, Hsu HK, Wang GJ. Effects of nonsteroidal antiinflammatory drugs and prostaglandins on osteoblastic functions. Biochem Pharmacol. 1999; 58:983–990.

5. Chang JK, Wang GJ, Tsai ST, Ho ML. Nonsteroidal antiinflammatory drug effects on osteoblastic cell cycle, cytotoxicity, and cell death. Connect Tissue Res. 2005; 46:200–210. doi: 10.1080/03008200500344025.